LAVA Medtech Acquisition, a blank check company led by healthcare VCs targeting the medtech sector, raised $100 million by offering 10 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50.
The company is led by CEO and Director Anthony Natale, a Managing Partner at Aperture Venture Partners, and Chairman Richard Emmitt, a Senior Partner of InnovaHealth Partners and a co-founder and General Partner of The Vertical Group.
LAVA Medtech Acquisition plans to target innovative, development- or early commercial-stage companies focused on clinically-impactful and high growth opportunities within medical devices, diagnostics, and digital health.
The Waltham, MA-based company plans to list on the Nasdaq under the symbol LVACU. RBC Capital Markets acted as sole bookrunner on the deal.
